Screener
Halozyme Therapeutics HALO Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryNoncurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's inventories?
- Halozyme Therapeutics (HALO) reported inventories of $14.84M in Q2 2026.
- How has Halozyme Therapeutics's inventories changed year-over-year?
- Halozyme Therapeutics's inventories decreased by 53.7% year-over-year, from $32.08M to $14.84M.
- What is the long-term trend for Halozyme Therapeutics's inventories?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's inventories has grown at a -19.3% compound annual growth rate (CAGR), from $60.75M to $20.77M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about Halozyme Therapeutics's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude